isocarboxazid has been researched along with Neuroleptic Malignant Syndrome in 1 studies
Isocarboxazid: An MAO inhibitor that is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in the treatment of panic disorder and the phobic disorders. (From AMA, Drug Evaluations Annual, 1994, p311)
Neuroleptic Malignant Syndrome: A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The neuroleptic malignant syndrome is a rare but dangerous complication of treatment with neuroleptics." | 1.28 | Neuroleptic malignant syndrome: a case report with post-mortem brain and muscle pathology. ( Dawson, A; Jones, EM, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jones, EM | 1 |
| Dawson, A | 1 |
1 other study available for isocarboxazid and Neuroleptic Malignant Syndrome
| Article | Year |
|---|---|
Neuroleptic malignant syndrome: a case report with post-mortem brain and muscle pathology.
Topics: Aged; Brain; Brain Ischemia; Chlorpromazine; Depressive Disorder; Drug Therapy, Combination; Female; | 1989 |